Skip to main content

Main menu

  • Home
  • Content
    • Latest
    • Archive
    • home
  • Info for
    • Authors
    • Reviewers
    • Subscribers
    • Institutions
    • Advertisers
    • Join SMJ
  • About Us
    • About Us
    • Editorial Office
    • Editorial Board
  • More
    • Advertising
    • Alerts
    • Feedback
    • Folders
    • Help
  • Other Publications
    • NeuroSciences Journal

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Saudi Medical Journal
  • Other Publications
    • NeuroSciences Journal
  • My alerts
  • Log in
Saudi Medical Journal

Advanced Search

  • Home
  • Content
    • Latest
    • Archive
    • home
  • Info for
    • Authors
    • Reviewers
    • Subscribers
    • Institutions
    • Advertisers
    • Join SMJ
  • About Us
    • About Us
    • Editorial Office
    • Editorial Board
  • More
    • Advertising
    • Alerts
    • Feedback
    • Folders
    • Help
  • Follow psmmc on Twitter
  • Visit psmmc on Facebook
  • RSS
Review ArticleSystematic Review
Open Access

Erlotinib for advanced hepatocellular carcinoma

A systematic review of phase II/III clinical trials

Jing Zhang, Yuan Zong, Gang-Zhu Xu and Ke Xing
Saudi Medical Journal November 2016, 37 (11) 1184-1190; DOI: https://doi.org/10.15537/smj.2016.11.16267
Jing Zhang
From the Department of Hepatopathy (Zhang), The Eighth Hospital of Xi’an, Department of Critical Care Medicine (Zong), Shaanxi Provincial People’s Hospital, Department of Surgery (Xu), First Affiliated Hospital of Xi’an Medical University, and the Department of Oncology (Xing), Honghui Hospital, Xi’an Jiaotong University, College of Medicine, Xi’an, China
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuan Zong
From the Department of Hepatopathy (Zhang), The Eighth Hospital of Xi’an, Department of Critical Care Medicine (Zong), Shaanxi Provincial People’s Hospital, Department of Surgery (Xu), First Affiliated Hospital of Xi’an Medical University, and the Department of Oncology (Xing), Honghui Hospital, Xi’an Jiaotong University, College of Medicine, Xi’an, China
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gang-Zhu Xu
From the Department of Hepatopathy (Zhang), The Eighth Hospital of Xi’an, Department of Critical Care Medicine (Zong), Shaanxi Provincial People’s Hospital, Department of Surgery (Xu), First Affiliated Hospital of Xi’an Medical University, and the Department of Oncology (Xing), Honghui Hospital, Xi’an Jiaotong University, College of Medicine, Xi’an, China
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ke Xing
From the Department of Hepatopathy (Zhang), The Eighth Hospital of Xi’an, Department of Critical Care Medicine (Zong), Shaanxi Provincial People’s Hospital, Department of Surgery (Xu), First Affiliated Hospital of Xi’an Medical University, and the Department of Oncology (Xing), Honghui Hospital, Xi’an Jiaotong University, College of Medicine, Xi’an, China
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
  • Article
  • Figures & Data
  • eLetters
  • Info & Metrics
  • References
  • PDF
Loading

Article Information

vol. 37 no. 11 1184-1190
DOI 
https://doi.org/10.15537/smj.2016.11.16267
PubMed 
27761555

Published By 
Saudi Medical Journal
Online ISSN 
1658-3175
History 
  • Received July 31, 2016
  • Accepted August 24, 2016
  • Published online November 1, 2016.

Copyright & Usage 
Copyright: © Saudi Medical Journal This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Author Information

  1. Jing Zhang, MD,
  2. Yuan Zong, MD,
  3. Gang-Zhu Xu, PhD and
  4. Ke Xing, MD⇑
  1. From the Department of Hepatopathy (Zhang), The Eighth Hospital of Xi’an, Department of Critical Care Medicine (Zong), Shaanxi Provincial People’s Hospital, Department of Surgery (Xu), First Affiliated Hospital of Xi’an Medical University, and the Department of Oncology (Xing), Honghui Hospital, Xi’an Jiaotong University, College of Medicine, Xi’an, China
  1. Address correspondence and reprint request to: Dr. Ke Xing, Department of Oncology, Honghui Hospital, Xi’an Jiaotong University, College of Medicine, Xi’an, China. E-mail: 1264201010{at}qq.com
View Full Text

Cited By...

  • 20 Citations
  • 19 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Identification of m6A- and ferroptosis-related lncRNA signature for predicting immune efficacy in hepatocellular carcinoma
    Hongjun Xie, Muqi Shi, Yifei Liu, Changhong Cheng, Lining Song, Zihan Ding, Huanzhi Jin, Xiaohong Cui, Yan Wang, Dengfu Yao, Peng Wang, Min Yao, Haijian Zhang
    Frontiers in Immunology 2022 13
  • Role of Systemic Therapy and Future Directions for Hepatocellular Carcinoma
    Jennifer Eatrides, Emilie Wang, Nishi Kothari, Richard Kim
    Cancer Control 2017 24 3
  • Emerging tyrosine kinase inhibitors for the treatment of hepatocellular carcinoma
    Laure de Rosamel, Jean-Frederic Blanc
    Expert Opinion on Emerging Drugs 2017 22 2
  • MiR-199-3p replacement affects E-cadherin expression through Notch1 targeting in hepatocellular carcinoma
    Catia Giovannini, Francesca Fornari, Rossella Dallo, Martina Gagliardi, Elisa Nipoti, Francesco Vasuri, Camelia Alexandra Coadă, Matteo Ravaioli, Luigi Bolondi, Laura Gramantieri
    Acta Histochemica 2018 120 2
  • Small Molecule Inhibitors for Hepatocellular Carcinoma: Advances and Challenges
    Monica A. Kamal, Yasmine M. Mandour, Mostafa K. Abd El-Aziz, Ulrike Stein, Hend M. El Tayebi
    Molecules 2022 27 17
  • Vorinostat-loaded titanium oxide nanoparticles (anatase) induce G2/M cell cycle arrest in breast cancer cells via PALB2 upregulation
    Shaimaa Abdel-Ghany, Sara Raslan, Huseyin Tombuloglu, Aly Shamseddin, Emre Cevik, Osama A. Said, Engy F. Madyan, Mehmet Senel, Ayhan Bozkurt, Suriya Rehman, Hussein Sabit
    3 Biotech 2020 10 9
  • FGF8 promotes cell proliferation and resistance to EGFR inhibitors via upregulation of EGFR in human hepatocellular carcinoma cells
    Yuanmin Pei, Xueling Sun, Xiwei Guo, Huashan Yin, Le Wang, Fugu Tian, Hongxi Jing, Xiaobo Liang, Jun Xu, Pengcheng Shi
    Oncology Reports 2017 38 4
  • T-box transcription factor 19 promotes hepatocellular carcinoma metastasis through upregulating EGFR and RAC1
    Xiaoyu Ji, Xiaoping Chen, Bixiang Zhang, Meng Xie, Tongyue Zhang, Xiangyuan Luo, Danfei Liu, Yangyang Feng, Yijun Wang, Mengyu Sun, Congxin Li, Wenjie Huang, Limin Xia
    Oncogene 2022 41 15
  • Emerging treatment modalities for systemic therapy in hepatocellular carcinoma
    Xin Qing, Wenjing Xu, Jingjing Zong, Xuanlong Du, Hao Peng, Yewei Zhang
    Biomarker Research 2021 9 1
  • Research Progresses of Targeted Therapy and Immunotherapy for Hepatocellular Carcinoma
    Tao Wang, Qiting Zhang, Ning Wang, Ziqi Liu, Bin Zhang, Yufen Zhao
    Current Medicinal Chemistry 2021 28 16
  • 2-Methoxyestradiol synergizes with Erlotinib to suppress hepatocellular carcinoma by disrupting the PLAGL2-EGFR-HIF-1/2α signaling loop
    Shufang Zheng, Jiaping Ni, Ying Li, Mingying Lu, Yuchen Yao, Haixin Guo, Meng Jiao, Tianle Jin, Haoying Zhang, Ansheng Yuan, Zhuo Wang, Yong Yang, Zhen Chen, Hongxi Wu, Weiwei Hu
    Pharmacological Research 2021 169
  • Using predictive machine learning models for drug response simulation by calibrating patient-specific pathway signatures
    Sepehr Golriz Khatami, Sarah Mubeen, Vinay Srinivas Bharadhwaj, Alpha Tom Kodamullil, Martin Hofmann-Apitius, Daniel Domingo-Fernández
    npj Systems Biology and Applications 2021 7 1
  • Insights into Growth Factors in Liver Carcinogenesis and Regeneration: An Ongoing Debate on Minimizing Cancer Recurrence after Liver Resection
    Ana I. Álvarez-Mercado, Albert Caballeria-Casals, Carlos Rojano-Alfonso, Jesús Chávez-Reyes, Marc Micó-Carnero, Alfredo Sanchez-Gonzalez, Araní Casillas-Ramírez, Jordi Gracia-Sancho, Carmen Peralta
    Biomedicines 2021 9 9
  • Experimental drug treatments for hepatocellular carcinoma: clinical trial failures 2015 to 2021
    Zachary J. Brown, D. Brock Hewitt, Timothy M. Pawlik
    Expert Opinion on Investigational Drugs 2022 31 7
  • Identification of an Oxidative Stress-Related LncRNA Signature for Predicting Prognosis and Chemotherapy in Patients With Hepatocellular Carcinoma
    Zixuan Zhong, Minxuan Xu, Jun Tan
    Pathology and Oncology Research 2022 28
  • Potential Molecular Targeted Therapy for Unresectable Hepatocellular Carcinoma
    Shashank Kumar, Abhay Kumar Pandey
    Current Oncology 2023 30 2
  • Titanium Oxide Nanoparticles Improve the Chemotherapeutic Action of Erlotinib in Liver Cancer Cells
    Shaimaa E. Abdel-Ghany, Eman El-Sayed, Nour Ashraf, Nada Mokhtar, Amany Alqosaibi, Emre Cevik, Ayhan Bozkurt, Eman W. Mohamed, Hussein Sabit
    Current Cancer Therapy Reviews 2020 16 4
  • Cucurbitacin I exerts its anticancer effects by inducing cell cycle arrest via the KAT2a-ube2C/E2F1 pathway and inhibiting HepG2-induced macrophage M2 polarization
    Xiaocheng Gong, Yunfei Liu, Keying Liang, Zixi Chen, Ke Ding, Li Qiu, Jinfen Wei, Hongli Du
    Biochemical and Biophysical Research Communications 2024 738
  • Role of Tyrosine Kinases in Gastrointestinal Malignancies
    L. V. K. S. Bhaskar, L. Saikrishna
    2018
PreviousNext
Back to top

In this issue

Saudi Medical Journal: 37 (11)
Saudi Medical Journal
Vol. 37, Issue 11
1 Nov 2016
  • Table of Contents
  • Cover (PDF)
  • Index by author
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on Saudi Medical Journal.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Erlotinib for advanced hepatocellular carcinoma
(Your Name) has sent you a message from Saudi Medical Journal
(Your Name) thought you would like to see the Saudi Medical Journal web site.
Citation Tools
Erlotinib for advanced hepatocellular carcinoma
Jing Zhang, Yuan Zong, Gang-Zhu Xu, Ke Xing
Saudi Medical Journal Nov 2016, 37 (11) 1184-1190; DOI: 10.15537/smj.2016.11.16267

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Erlotinib for advanced hepatocellular carcinoma
Jing Zhang, Yuan Zong, Gang-Zhu Xu, Ke Xing
Saudi Medical Journal Nov 2016, 37 (11) 1184-1190; DOI: 10.15537/smj.2016.11.16267
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Acknowledgment
    • Footnotes
    • References
  • Figures & Data
  • eLetters
  • References
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Pocket-creation method versus conventional method of endoscopic submucosal dissection for early gastric cancer
  • Breast cancer incidence after hormonal treatment for infertility
  • Advancing genetic counselling in Southern Africa
Show more Systematic Review

Similar Articles

CONTENT

  • home

JOURNAL

  • home

AUTHORS

  • home
Saudi Medical Journal

© 2025 Saudi Medical Journal Saudi Medical Journal is copyright under the Berne Convention and the International Copyright Convention.  Saudi Medical Journal is an Open Access journal and articles published are distributed under the terms of the Creative Commons Attribution-NonCommercial License (CC BY-NC). Readers may copy, distribute, and display the work for non-commercial purposes with the proper citation of the original work. Electronic ISSN 1658-3175. Print ISSN 0379-5284.

Powered by HighWire